KR20200018436A - 암 치료를 위한 조합 요법 - Google Patents

암 치료를 위한 조합 요법 Download PDF

Info

Publication number
KR20200018436A
KR20200018436A KR1020197036164A KR20197036164A KR20200018436A KR 20200018436 A KR20200018436 A KR 20200018436A KR 1020197036164 A KR1020197036164 A KR 1020197036164A KR 20197036164 A KR20197036164 A KR 20197036164A KR 20200018436 A KR20200018436 A KR 20200018436A
Authority
KR
South Korea
Prior art keywords
cancer
agent
subject
inhibits
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020197036164A
Other languages
English (en)
Korean (ko)
Inventor
드미트리 보빌레브
브루스 데주베
펭 선
앤드류 알. 퍼거슨
Original Assignee
테사로, 인코포레이티드
머크 샤프 앤 도메 비.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 테사로, 인코포레이티드, 머크 샤프 앤 도메 비.브이. filed Critical 테사로, 인코포레이티드
Publication of KR20200018436A publication Critical patent/KR20200018436A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K1/00—Housing animals; Equipment therefor
    • A01K1/01—Removal of dung or urine ; Removal of manure from stables
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T7/00—Image analysis
    • G06T7/20—Analysis of motion
    • G06T7/215—Motion-based segmentation
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01R—ELECTRICALLY-CONDUCTIVE CONNECTIONS; STRUCTURAL ASSOCIATIONS OF A PLURALITY OF MUTUALLY-INSULATED ELECTRICAL CONNECTING ELEMENTS; COUPLING DEVICES; CURRENT COLLECTORS
    • H01R13/00—Details of coupling devices of the kinds covered by groups H01R12/70 or H01R24/00 - H01R33/00
    • H01R13/46—Bases; Cases
    • H01R13/516—Means for holding or embracing insulating body, e.g. casing, hoods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Environmental Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Multimedia (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020197036164A 2017-05-09 2018-05-09 암 치료를 위한 조합 요법 Pending KR20200018436A (ko)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201762503879P 2017-05-09 2017-05-09
US62/503,879 2017-05-09
US201762508359P 2017-05-18 2017-05-18
US62/508,359 2017-05-18
US201762556255P 2017-09-08 2017-09-08
US62/556,255 2017-09-08
US201862634789P 2018-02-23 2018-02-23
US62/634,789 2018-02-23
US201862646332P 2018-03-21 2018-03-21
US62/646,332 2018-03-21
US201862648327P 2018-03-26 2018-03-26
US62/648,327 2018-03-26
PCT/US2018/031876 WO2018208968A1 (en) 2017-05-09 2018-05-09 Combination therapies for treating cancer

Publications (1)

Publication Number Publication Date
KR20200018436A true KR20200018436A (ko) 2020-02-19

Family

ID=64105496

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197036164A Pending KR20200018436A (ko) 2017-05-09 2018-05-09 암 치료를 위한 조합 요법

Country Status (14)

Country Link
US (2) US12156872B2 (https=)
EP (1) EP3621592A4 (https=)
JP (2) JP2020519621A (https=)
KR (1) KR20200018436A (https=)
CN (1) CN110831580A (https=)
AU (3) AU2018264992A1 (https=)
BR (1) BR112019023591A2 (https=)
CA (1) CA3063201A1 (https=)
IL (1) IL270511B2 (https=)
MA (1) MA48637A (https=)
MX (1) MX2019013373A (https=)
TW (2) TW202444417A (https=)
WO (1) WO2018208968A1 (https=)
ZA (1) ZA201907395B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
CN110944638A (zh) 2017-03-27 2020-03-31 特沙诺有限公司 尼拉帕尼组合物
MA48475A (fr) 2017-04-24 2020-03-04 Tesaro Inc Procédés de fabrication de niraparib
TW202444417A (zh) 2017-05-09 2024-11-16 美商提薩羅有限公司 治療癌症的組合療法
KR20200005662A (ko) 2017-05-18 2020-01-15 테사로, 인코포레이티드 암을 치료하기 위한 조합 요법
TWI843707B (zh) 2017-09-26 2024-06-01 美商提薩羅有限公司 尼拉帕尼（ｎｉｒａｐａｒｉｂ）調配物
MX2020003770A (es) 2017-09-30 2020-07-29 Tesaro Inc Terapias de combinacion para tratar cancer.
EA202090655A1 (ru) 2017-10-06 2020-12-07 Тесаро, Инк. Комбинированные терапевтические средства и их применение
TW201938165A (zh) * 2017-12-18 2019-10-01 美商輝瑞股份有限公司 治療癌症的方法及組合療法
CN109053895B (zh) 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
CN113116881B (zh) * 2019-12-31 2025-03-07 甫康（上海）健康科技有限责任公司 一种用于治疗肿瘤的药物组合及其应用
EP4190819A4 (en) * 2021-03-12 2024-08-14 Akeso Biopharma, Inc. PHARMACEUTICAL COMBINATION CONTAINING BISPECIFIC ANTI-PD-1-ANTI-VEGFA ANTIBODY, AND USE THEREOF
US20240366584A1 (en) 2021-06-21 2024-11-07 Tesaro, Inc. Combination treatment of cancer with a parp inhibitor and a lipophilic statin
US20250352534A1 (en) 2022-02-15 2025-11-20 Tesaro, Inc. Use of Niraparib for the Treatment of Brain Cancer
WO2025128263A1 (en) * 2023-12-15 2025-06-19 Pharmaessentia Corporation Anti-pd-1 monoclonal antibody and methods of preparation thereof

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2059571T3 (es) 1988-01-19 1994-11-16 Takeda Chemical Industries Ltd Fumagilina como agente angiostatico.
CA1329771C (en) 1988-09-01 1994-05-24 Shoji Kishimoto Angiogenesis inhibitory agent
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
US9707302B2 (en) * 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
CA2647545C (en) 2006-04-03 2016-02-23 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors
JP4611444B2 (ja) 2007-01-10 2011-01-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
US7732491B2 (en) 2007-11-12 2010-06-08 Bipar Sciences, Inc. Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
EP2217244A4 (en) 2007-11-12 2011-08-31 Bipar Sciences Inc TREATMENT OF NUTRITIONAL CANCER AND EGG CANCER WITH A PARP INHIBITOR ALONE OR IN COMBINATION WITH ANTITUMOROUS MEDICINES
KR101653548B1 (ko) 2008-01-08 2016-09-02 머크 샤프 앤드 돔 리미티드 2-｛4-［（3ｓ）-피페리딘-3-일］페닐｝-2ｈ-인다졸-7-카복스아미드의 약제학적으로 허용되는 염
WO2009087474A2 (en) 2008-01-08 2009-07-16 Akthelia Pharmaceuticals Agonists for antimicrobial peptide systems
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
CN102307475A (zh) 2009-02-04 2012-01-04 彼帕科学公司 用与生长因子抑制剂组合的parp抑制剂治疗肺癌
PL2504364T3 (pl) 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
WO2011153383A1 (en) * 2010-06-04 2011-12-08 Bipar Science, Inc. Methods of treating platinum-resistant recurrent ovarian cancer with 4-iodo-3-nitrobenzamide in combination with an anti-metabolite and a platinum compound
EP3012329B1 (en) 2010-06-18 2017-10-25 Myriad Genetics, Inc. Methods and materials for assessing loss of heterozygosity
WO2012027224A1 (en) 2010-08-24 2012-03-01 Dana-Farber Cancer Institute, Inc. Methods for predicting anti-cancer response
CA2742342A1 (en) 2011-02-12 2012-08-12 Baylor Research Institute Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
WO2013182645A1 (en) 2012-06-07 2013-12-12 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
EP2928473B1 (en) 2012-12-07 2017-06-28 Merck Sharp & Dohme Corp. Regioselective n-2 arylation of indazoles
US9738915B2 (en) 2012-12-07 2017-08-22 Merck Sharp & Dohme Corp. Biocatalytic transamination process
US9850542B2 (en) 2013-03-04 2017-12-26 Board Of Regents, The University Of Texas System Gene signature to predict homologous recombination (HR) deficient cancer
US20150071910A1 (en) 2013-03-15 2015-03-12 Genentech, Inc. Biomarkers and methods of treating pd-1 and pd-l1 related conditions
SMT202100065T1 (it) 2013-05-02 2021-03-15 Anaptysbio Inc Anticorpi diretti contro la proteina della morte programmata (pd-1)
WO2015086473A1 (en) * 2013-12-09 2015-06-18 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
CN105917007A (zh) * 2014-01-16 2016-08-31 克洛维斯肿瘤有限公司 Parp抑制剂用以治疗显示杂合性丧失的乳腺癌或卵巢癌患者的用途
WO2015116868A2 (en) 2014-01-29 2015-08-06 Caris Mpi, Inc. Molecular profiling of immune modulators
PL3102605T3 (pl) 2014-02-04 2019-06-28 Pfizer Inc. Połączenie antagonisty pd-1 i inhibitora vegfr do leczenia nowotworu
KR20160146747A (ko) 2014-03-31 2016-12-21 제넨테크, 인크. 항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법
WO2015184145A1 (en) 2014-05-28 2015-12-03 Eisai R&D Management Co., Ltd. Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
US20150344968A1 (en) * 2014-05-30 2015-12-03 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Methods for determining parp inhibitor and platinum resistance in cancer therapy
US20160160294A1 (en) 2014-12-08 2016-06-09 Tesaro Methods and materials for predicting response to niraparib
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
FI3277321T3 (fi) 2015-04-01 2024-10-31 Anaptysbio Inc T-soluimmunoglobuliinia ja musiiniproteiini 3:a (tim-3) vastaan suunnattuja vasta-aineita
JP2018514550A (ja) 2015-04-28 2018-06-07 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置
MX2017015937A (es) * 2015-06-08 2018-12-11 Genentech Inc Métodos de tratamiento del cáncer con anticuerpos anti-ox40 y antagonistas de unión al eje de pd-1.
JP6980980B2 (ja) * 2015-06-25 2021-12-15 イミューノメディクス、インコーポレイテッドImmunomedics, Inc. 抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する
JP7042739B2 (ja) * 2015-08-20 2022-03-28 イプセン バイオファーム リミティド 癌処置のためのリポソーム型イリノテカン及びｐａｒｐ阻害薬を使用する併用療法
SG11201803462PA (en) 2015-10-26 2018-05-30 Medivation Tech Llc Treatment of small cell lung cancer with a parp inhibitor
US20210322415A1 (en) 2016-02-15 2021-10-21 Astrazeneca Ab Methods comprising fixed intermittent dosing of cediranib
SG11201811564QA (en) 2016-06-29 2019-01-30 Tesaro Inc Methods of treating ovarian cancer
CN110087730B (zh) 2016-09-27 2023-03-28 百济神州(苏州)生物科技有限公司 使用包含parp抑制剂的组合产品治疗癌症
JP2019533458A (ja) 2016-11-01 2019-11-21 アナプティスバイオ インコーポレイティッド プログラム死１（ｐｄ−１）に対する抗体
MX2019005116A (es) 2016-11-01 2019-11-12 Anaptysbio Inc Anticuerpos dirigidos contra la proteina de inmunoglobulina de linfocitos t y de mucina 3 (tim-3).
AU2018206481B2 (en) 2017-01-09 2025-02-27 Tesaro, Inc. Methods of treating cancer with anti-PD-1 antibodies
WO2018129553A1 (en) * 2017-01-09 2018-07-12 Tesaro, Inc. Methods of treating cancer with anti-tim-3 antibodies
CN110944638A (zh) 2017-03-27 2020-03-31 特沙诺有限公司 尼拉帕尼组合物
KR20190130625A (ko) 2017-03-27 2019-11-22 테사로, 인코포레이티드 니라파립 제제
MA48475A (fr) 2017-04-24 2020-03-04 Tesaro Inc Procédés de fabrication de niraparib
SG11201909395TA (en) 2017-04-27 2019-11-28 Tesaro Inc Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
TW202444417A (zh) 2017-05-09 2024-11-16 美商提薩羅有限公司 治療癌症的組合療法
KR20200005662A (ko) 2017-05-18 2020-01-15 테사로, 인코포레이티드 암을 치료하기 위한 조합 요법
US20200129482A1 (en) 2017-06-26 2020-04-30 Abbvie Inc. Treatment of non-small cell lung cancer
TWI843707B (zh) 2017-09-26 2024-06-01 美商提薩羅有限公司 尼拉帕尼（ｎｉｒａｐａｒｉｂ）調配物
MX2020003770A (es) 2017-09-30 2020-07-29 Tesaro Inc Terapias de combinacion para tratar cancer.
EA202090655A1 (ru) * 2017-10-06 2020-12-07 Тесаро, Инк. Комбинированные терапевтические средства и их применение
US20210106574A1 (en) 2017-12-27 2021-04-15 Tesaro, Inc. Methods of Treating Cancer
CN111918667A (zh) 2018-02-05 2020-11-10 特沙诺有限公司 儿科尼拉帕尼配制剂和儿科治疗方法
EA201992594A1 (ru) 2018-03-26 2020-03-20 Тесаро, Инк. Комбинированные терапии для лечения рака
US11970530B2 (en) 2020-08-13 2024-04-30 Astrazeneca Ab Methods of treating homologous recombination deficient cancer

Also Published As

Publication number Publication date
JP7717749B2 (ja) 2025-08-04
AU2021218080B2 (en) 2023-12-14
AU2023274126A1 (en) 2024-02-01
MX2019013373A (es) 2020-08-03
ZA201907395B (en) 2025-01-29
IL270511B1 (en) 2024-08-01
EP3621592A1 (en) 2020-03-18
EP3621592A4 (en) 2021-03-17
IL270511B2 (en) 2024-12-01
US12156872B2 (en) 2024-12-03
US20200289493A1 (en) 2020-09-17
AU2021218080A1 (en) 2021-09-09
AU2018264992A1 (en) 2019-12-05
TW202444417A (zh) 2024-11-16
IL270511A (en) 2019-12-31
CN110831580A (zh) 2020-02-21
TW201906632A (zh) 2019-02-16
JP2020519621A (ja) 2020-07-02
BR112019023591A2 (pt) 2020-05-26
CA3063201A1 (en) 2018-11-15
JP2023093603A (ja) 2023-07-04
US20240226082A1 (en) 2024-07-11
TWI879716B (zh) 2025-04-11
WO2018208968A1 (en) 2018-11-15
MA48637A (fr) 2021-03-17

Similar Documents

Publication Publication Date Title
JP7717749B2 (ja) 癌を治療するための併用療法
US11661453B2 (en) Combination therapies for treating cancer with niraparib and PD-1 inhibitors
JP7337805B2 (ja) がんを処置する方法
ES2945745T3 (es) Métodos de tratamiento de cánceres con anticuerpos anti-PD-1
JP6591428B2 (ja) 癌治療のためのｐｄ−１拮抗薬およびｖｅｇｆｒ阻害剤の組み合わせ
JP7166278B2 (ja) がんの治療のための抗ｐｄ－ｌ１抗体およびｄｎａ－ｐｋインヒビターの併用
TW202024638A (zh) 治療癌症之方法
JP2020517629A5 (https=)
JP2021533090A (ja) 併用療法
EA044067B1 (ru) Комбинированные терапии для лечения рака
EA043391B1 (ru) Способы лечения рака с помощью антител к pd-1

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

F13 Ip right granted in full following pre-grant review

Free format text: ST27 STATUS EVENT CODE: A-3-4-F10-F13-REX-PX0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701